The final judgment removes the last substantive legal overhang from the Alexion acquisition earn-out dispute. With the case now resolved at the trial level, the only remaining step is a potential appeal by SRS, which would require posting a bond. Monitor for any notice of appeal from SRS, but the risk of a material adverse outcome for AstraZeneca is now minimal.
Price Chart
Executive Summary
The Delaware Court of Chancery entered judgment in favor of Alexion (now AstraZeneca) on the remaining Milestone 1 CRE claim, finding that SRS failed to prove a breach. The court also ruled that postjudgment interest on the entire judgment amount will be calculated using the contract rate as of the date of judgment, resolving a dispute over the bond amount for the stay pending appeal. This final order resolves the last substantive issue in the case, removing further uncertainty.
Court Ruling Details
Key Facts
- Judgment entered in Alexion's favor on Count I regarding Milestone 1 commercially reasonable efforts claim.
- SRS's claim for Milestone 1 CRE breach was deemed waived or failed on the merits.
- Postjudgment interest will be calculated using the contract rate as of the date of judgment for all damages amounts.
- The ruling resolves the dispute over the bond amount securing the stay pending appeal.
- This is a final order on the remaining issues in the case, following prior liability and damages opinions.
Financial Impact
No new damages awarded; the ruling resolves the final substantive issue in a case where prior opinions had already established liability and damages. The postjudgment interest ruling may modestly affect the total payout but the amount is not specified in this document.
Risk Factors
- SRS may appeal the ruling to the Delaware Supreme Court, prolonging the case.
- The exact dollar amount of the bond and total judgment is not specified in this document; a large bond requirement could be a minor negative if appealed.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-d6fb4166dc-AZN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $171.49 (−0.63%) |
Oct 15, 2026 11d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $171.49 (+3.68%) |
Oct 5, 2026 20d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $171.49 (+9.56%) |
Oct 2, 2026 24d ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $171.49 (+9.30%) |
Oct 2, 2026 24d ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $171.49 (+9.56%) |
Oct 1, 2026 24d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $171.49 (+8.74%) |
Oct 1, 2026 24d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $171.49 (+8.74%) |
Sep 29, 2026 27d ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $171.49 (+4.43%) |
Sep 23, 2026 4w ago | 6-K | $163.33 $164.56 | ▲ +0.75% | ▲ +0.84% | $171.49 (+5.00%) |
Sep 21, 2026 5w ago | 6-K | $168.10 $168.37 | ▲ +0.16% | ▲ +0.18% | $171.49 (+2.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers